

## DAFTAR PUSTAKA

Ababa, A. *et al.* (2022) 'Adherence to Chemotherapy among Women with Breast Cancer Treated at Tikur Anbessa Specialized and Teaching', 23, pp. 3035–3041. doi: 10.31557/APJCP.2022.23.9.3035.

Abdulwassi, H. K. *et al.* (2020) 'Recurrence rates and long-term survival factors in young women with breast cancer', *Saudi Medical Journal*, 41(4), pp. 393–399. doi: 10.15537/SMJ.2020.4.24987.

Abrial, S. C. *et al.* (2005) 'High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.', *Breast cancer research and treatment*. Netherlands, 94(3), pp. 255–263. doi: 10.1007/s10549-005-9008-8.

Alkabban, F. M. and Ferguson, T. (2021) *Breast Cancer*, StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK482286/> (Accessed: 25 December 2021).

Bai, L. *et al.* (2013) 'Lymph Node Ratio is More Predictive than Traditional Lymph Node Stratification in Lymph Node Positive Invasive Breast Cancer', 14, pp. 753–757.

Burstein, H. J. *et al.* (2019) 'Estimating the benefits of therapy for early-stage breast cancer : the St . Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019', *Incidence and mortality of nasopharyngeal carcinoma*. Elsevier Masson SAS, 30(10), pp. 1541–1557. doi: 10.1093/annonc/mdz235.

Canadian Cancer Society (2022) *Risk of recurrence after surgery and additional treatments*. Available at: <https://cancer.ca/en/cancer-information/cancer-types/breast/treatment/risk-of-breast-cancer-recurrence-and-adjuvant-therapy>.

Capulli, M. *et al.* (2012) 'Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs \_ Enhanced Reader.pdf', *Journal of Bone and Mineral Research*, 27(11), pp. 2387–2398.

Chirgwin, J. H. *et al.* (2023) 'Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole , Alone and in Sequence', 34(21). doi: 10.1200/JCO.2015.63.8619.

Choong, G. M., Cullen, G. D. and O'Sullivan, C. C. (2020) 'Evolving standards of care and new challenges in the management of HER2-positive.pdf', *Cancer Journal for Clinicians*, 20(5), pp. 355–374.

Cockburn, J. G. *et al.* (2016) 'The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures', *BMC Cancer*. BMC Cancer, 16(1), pp. 1–11. doi: 10.1186/s12885-016-2501-0.

Colditz, G. A. *et al.* (2012) 'Family history and risk of breast cancer: nurses' health study.', *Breast cancer research and treatment*, 133(3), pp. 1097–1104. doi: 10.1007/s10549-012-1985-9.

Curigliano, G. *et al.* (2017) 'De-escalating and escalating treatments for early-stage breast cancer : the St . Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Cancer 2017 Special article', (June), pp. 1700–1712. doi: 10.1093/annonc/mdx308.

- Dahlan, M. S. (2013) *Besar Sampel dan Cara Pengambilan Sampel*. Tiga. Jakarta: Salemba Medika.
- Dong, W. *et al.* (2014) 'Molecular Classifications of Breast Cancer', *Journal of Surgical Research*, 185(2), pp. 697–703. doi: 10.1016/j.jss.2013.06.048.
- Dowsett, M. *et al.* (2007) 'Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer', pp. 167–170. doi: 10.1093/jnci/djk020.
- Dumars, C. *et al.* (2016) 'Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma', *Oncotarget*, 7(48).
- Escala-Garcia, M. *et al.* (2020) 'Breast cancer risk factors and their effects on survival: a Mendelian randomisation study', *BMC Medicine*. BMC Medicine, 18(1), pp. 1–10. doi: 10.1186/s12916-020-01797-2.
- Fan, L. *et al.* (2015) 'Current Status and Future Projections of Breast Cancer in Asia', pp. 372–378. doi: 10.1159/000441818.
- Fendereski, A. *et al.* (2022) 'Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes', *BMC Women's Health*. BioMed Central, 22(1), pp. 1–12. doi: 10.1186/s12905-022-01846-3.
- Feng, Y. *et al.* (2018) 'Breast cancer development and progression : Risk factors , cancer stem cells , signaling pathways , genomics , and molecular pathogenesis', *Genes & Diseases*. Elsevier Ltd, 5(2), pp. 77–106. doi: 10.1016/j.gendis.2018.05.001.
- Goldhirsch, A. *et al.* (2013) 'Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013', (March), pp. 2206–2223. doi: 10.1093/annonc/mdt303.
- Gourgou-Bourgade, S. *et al.* (2015) 'Guidelines for time-to-event end point definitions in breast cancer trials: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)', *Annals of Oncology*, 26(5), pp. 873–879. doi: 10.1093/annonc/mdv106.
- Guarneri, V. *et al.* (2009) 'A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy', *Annals of Oncology*. Elsevier Masson SAS, 20(7), pp. 1193–1198. doi: 10.1093/annonc/mdn761.
- Harbeck, N. *et al.* (2019) 'Breast cancer', *Nature Reviews Disease Primers*, 5(1). doi: 10.1038/s41572-019-0111-2.
- Hortobagyi, G. N. *et al.* (2018) 'Breast', in Amin, M. B. (ed.) *AJCC Cancer Staging Manual*, . 8th edn. American College of Surgeons. doi: 10.1002/jso.2930040408.
- Houvenaeghel, G. *et al.* (2021) 'Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer , results from a large , national , multicenter , retrospective cohort study', *ESMO Open*. Elsevier Ltd., 6(6), p. 100316. doi: 10.1016/j.esmoop.2021.100316.
- Huober, J. *et al.* (2023) 'Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy', *npj Breast Cancer*. Springer US, 9(1). doi: 10.1038/s41523-023-00525-2.
- Kanyilmaz, G. (2019) 'Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors', 15(4), pp. 256–261. doi: 10.5152/ejbh.2019.4778.

- Karihtala, P. *et al.* (2020) 'Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital', *BMJ Open*, 10(10), pp. 1–6. doi: 10.1136/bmjopen-2020-038798.
- Kariri, Y. A. and Aleskandarany, M. A. (2020) 'Molecular Complexity of Lymphovascular Invasion : The Role of Cell Migration in Breast Cancer as a Prototype', pp. 218–231. doi: 10.1159/000508337.
- Kasangian, A. A. *et al.* (2017) 'The prognostic role of tumor size in early breast cancer in the era of molecular biology', *PLoS ONE*, 12(12), pp. 1–12. doi: 10.1371/journal.pone.0189127.
- Kermani, T. A. *et al.* (2019) 'Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors', *Biomedical Research and Therapy*, 6(2), pp. 2986–2991.
- Kim, H. *et al.* (2021) 'Prognosis of patients with axillary lymph node metastases from occult breast cancer : analysis of multicenter data', 39(2), pp. 107–112.
- Kim, J. *et al.* (2018) 'The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis', pp. 43–47.
- Kim, Y., Yoo, K. and Goodman, M. T. (2015) 'Differences in Incidence , Mortality and Survival of Breast Cancer by Regions and Countries in Asia and Contributing Factors', 16, pp. 2857–2870.
- Lafourcade, A. *et al.* (2018) 'Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences : the French E3N cohort'. *BMC Cancer*, pp. 1–9.
- Lehmann, B. D. *et al.* (2011) 'Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies', *Journal of Clinical Investigation*, 121(7), pp. 2750–2767. doi: 10.1172/JCI45014.
- Leong, S. P. L. *et al.* (2010) 'Is Breast Cancer the Same Disease in Asian and Western Countries ?', pp. 2308–2324. doi: 10.1007/s00268-010-0683-1.
- Lian, W. *et al.* (2020) 'Effect of node status on breast cancer survival by subtype : a single-center retrospective cohort study', *European Journal of Breast Health*, 9(10), pp. 5900–5908. doi: 10.21037/tcr-20-1117.
- Liu, Y. L. *et al.* (2017) 'Lymphovascular Invasion is an Independent Predictor of Survival in Breast Cancer after Neoadjuvant Chemotherapy', *Breast Cancer: Targets and Therapy*, 157(Lvi), pp. 555–564. doi: 10.1007/s10549-016-3837-5.Lymphovascular.
- Mackey, J. R. *et al.* (2013) 'Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.', *The Lancet. Oncology*. England, 14(1), pp. 72–80. doi: 10.1016/S1470-2045(12)70525-9.
- Makar, W. and Lasheen, S. (2020) 'Assessment of the Prognostic Role of Ki-67 and Its Optimal Cutoff Value in Early Breast Cancer : A Retrospective Analysis', 16(2), pp. 35–41.
- Mascarel, I. De *et al.* (2009) 'D2-40 in breast cancer : should we detect more vascular emboli ?', pp. 216–222. doi: 10.1038/modpathol.2008.151.
- Migeotte, A. *et al.* (2021) 'Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer', *BMC Cancer*, 21(1), p. 1204. doi: 10.1186/s12885-021-08950-x.
- Mittal, A. *et al.* (2023) 'Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-

- analysis', *Critical Reviews in Oncology/Hematology*. Elsevier B.V., 181(October 2022), p. 103880. doi: 10.1016/j.critrevonc.2022.103880.
- Moe, A. *et al.* (2008) 'Noncompliance with adjuvant radiation , chemotherapy , or hormonal therapy in breast cancer patients', pp. 500–504. doi: 10.1016/j.amjsurg.2008.06.027.
- Momenimovahed, Z. and Salehiniya, H. (2019) 'Epidemiological characteristics of and risk factors for breast cancer in the world', *Breast Cancer: Targets and Therapy*, 11, pp. 151–164. doi: 10.2147/BCTT.S176070.
- Narod, S. A. (2018) 'Personalised medicine and population health: breast and ovarian cancer', *Human Genetics*, 137(10), pp. 769–778. doi: 10.1007/s00439-018-1944-6.
- Nguyen, D. *et al.* (2020) 'Association of Independent Prognostic Factors and Treatment Modality with Survival and Recurrence Outcomes in Breast Cancer', *JAMA Network Open*, 3(7), pp. 1–11. doi: 10.1001/jamanetworkopen.2020.7213.
- Niño, E. *et al.* (2020) 'Healthcare providers ' adherence to breast cancer guidelines in Europe : a systematic literature review', *Breast Cancer Research and Treatment*. Springer US, 181(3), pp. 499–518. doi: 10.1007/s10549-020-05657-8.
- Nishimura, R. *et al.* (2010) 'Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer.', *Experimental and therapeutic medicine*, 1(5), pp. 747–754. doi: 10.3892/etm.2010.133.
- Nishimura, R. *et al.* (2022) 'An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer', pp. 1–8. doi: 10.3892/ol.2022.13366.
- Nowikiewicz, T., Wiśniewska, M. and Wiśniewski, M. (2006) 'Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz – analysis of more than six years of follow-up'. doi: 10.5114/wo.2015.54387.
- Pagano, M. T., Ortona, E. and Dupuis, M. L. (2020) 'A Role for Estrogen Receptor alpha36 in Cancer Progression', 11(July), pp. 1–7. doi: 10.3389/fendo.2020.00506.
- PDQ Screening and Prevention Editorial Board (2021) 'Breast Cancer Screening (PDQ®): Health Professional Version.', in *PDQ Cancer Information Summaries*. Bethesda (MD), United States: National Cancer Institute.
- Pedersen, R. N. *et al.* (2022) 'The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis', 114, pp. 391–399.
- Perou, C. M. and Borresen-Dale, A. L. (2011) 'Systems biology and genomics of breast cancer', *Cold Spring Harbor Perspectives in Biology*, 3(2), pp. 1–17. doi: 10.1101/cshperspect.a003293.
- Phung, M. T., Tin Tin, S. and Elwood, J. M. (2019) 'Prognostic models for breast cancer: A systematic review', *BMC Cancer*. BMC Cancer, 19(1), pp. 1–18. doi: 10.1186/s12885-019-5442-6.
- Proskurina, A. S. *et al.* (2016) 'Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen', *BMC Cancer*. BMC Cancer, pp. 1–9. doi: 10.1186/s12885-016-2711-5.
- Reyes, N. *et al.* (2016) 'The small leucine rich proteoglycan fibromodulin is



overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue.’, *Cancer biomarkers : section A of Disease markers*. Netherlands, 16(1), pp. 191–202. doi: 10.3233/CBM-150555.

Sabiyanto, V. T., Widiasih, R. and Solehati, T. (2019) ‘BREAST CANCER PATIENTS’ COMPLIANCE ON CHEMOTHERAPY : A DESCRIPTIVE STUDY’, *Journal of Maternity Care and Reproductive Health*, 2(3), pp. 208–222.

Shi, Q. and Sargent, D. J. (2009) ‘Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.’, *International journal of clinical oncology*. Japan, 14(2), pp. 102–111. doi: 10.1007/s10147-009-0885-4.

Singh, A. S., Bhardwaj, B. S. and Goswami, B. C. (2022) ‘Disease Free Survival in Locally Advanced Breast Cancer : An Analysis of Clinical and Pathological Factors’, 7(1), pp. 21–27. doi: 10.31557/APJCC.2022.7.1.21.

Soliman, N. A. and Yussif, S. M. (2016) ‘Ki-67 as a prognostic marker according to breast cancer molecular subtype’, *Cancer Biology and Medicine*, 13(4), pp. 496–504. doi: 10.20892/j.issn.2095-3941.2016.0066.

Song, Y. J. *et al.* (2011) ‘The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer.’, *Journal of breast cancer*, 14(3), pp. 198–203. doi: 10.4048/jbc.2011.14.3.198.

Sonnenschein, C. and Soto, A. (2016) ‘Carcinogenesis explained within the context of a theory of organisms’, *Progress in Biophysics and Molecular Biology*, 122(1), pp. 70–76. doi: 10.1016/j.pbiomolbio.2016.07.004.

Stanisławek, A. (2021) ‘Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies— An Updated Review’, *Cancers*, 13(7), pp. 1–30.

Sun, Y. S. *et al.* (2017) ‘Risk factors and preventions of breast cancer’, *International Journal of Biological Sciences*, 13(11), pp. 1387–1397. doi: 10.7150/ijbs.21635.

Tang, C. *et al.* (2017) ‘Lymph node status have a prognostic impact in breast cancer patients with distant metastasis’, *PLoS ONE*, 12(8), pp. 1–9. doi: 10.1371/journal.pone.0182953.

Thangarajah, F. *et al.* (2017) ‘A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases’, 1964, pp. 1957–1964. doi: 10.21873/anticancerres.11536.

The Global Cancer Observatory (2020) *Global Burden of Cancer Study (Globocan) 2020*. Available at: <https://gco.iarc.fr/today>.

Tonello, F. *et al.* (2019) ‘Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer’, *European Journal of Breast Health*, 15(2), pp. 76–84. doi: 10.5152/ejbh.2019.4414.

Valenti, G. *et al.* (2017) ‘Cancer Stem Cells Regulate Cancer-Associated Fibroblasts via Activation of Hedgehog Signaling in Mammary Gland Tumors’, 77(8), pp. 2134–2148. doi: 10.1158/0008-5472.CAN-15-3490.

Villarreal-garza, C. *et al.* (2023) ‘Clinical and Epidemiological Profile of Breast Cancer in Mexico : Results of the Seguro Popular’, 3(6), pp. 757–764. doi: 10.1200/JGO.2016.007377.

Villegas, S. L. *et al.* (2021) ‘Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials’, *European Journal of Cancer*, 148,

pp. 159–170. doi: 10.1016/j.ejca.2021.02.020.

Wee, P. and Wang, Z. (2017) ‘Epidermal Growth Factor Receptor Cell Proliferation’, pp. 1–45. doi: 10.3390/cancers9050052.

Wijayanto, A. *et al.* (2022) ‘Survivability Rates Based on Molecular Subtype, Stage and Metastasis of 36 months cohort in Breast Cancer Patients’, *Nusantara Medical Science Journal*, 7(1), pp. 29–38. doi: 10.20956/nmsj.v7i1.20092.

Wilkie, J. *et al.* (2020) ‘Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer’, *Clinical Breast Cancer*, 20(1), pp. 33–40. doi: <https://doi.org/10.1016/j.clbc.2019.06.010>.

Wu, N. *et al.* (2020) ‘Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis’, *Clinical and Translational Oncology*, 22(4), pp. 474–485. doi: 10.1007/s12094-019-02149-0.

Yang, X. *et al.* (2020) ‘Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: an analysis of 4501 consecutive patients’, *The Breast*. Elsevier Ltd. doi: 10.1016/j.breast.2020.05.008.

Yang, Y. *et al.* (2018) ‘HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1’, 78(2), pp. 422–436. doi: 10.1158/0008-5472.CAN-17-1533.

Yerushalmi, R. *et al.* (2010) ‘Ki67 in breast cancer: prognostic and predictive potential.’, *The Lancet. Oncology*. England, 11(2), pp. 174–183. doi: 10.1016/S1470-2045(09)70262-1.

Zhong, Y. M., Tong, F. and Shen, J. (2022) ‘Lympho - vascular invasion impacts the prognosis in breast - conserving surgery : a systematic review and meta - analysis’, *BMC Cancer*. BioMed Central, pp. 1–9. doi: 10.1186/s12885-022-09193-0.

Ziller, V. *et al.* (2013) ‘Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study’.